E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 4/30/2007 in the Prospect News Special Situations Daily.

Greatbatch to acquire Enpath in $102 million deal

By Lisa Kerner

Charlotte, N.C., April 30 - Greatbatch Ltd. entered into a definitive merger agreement to acquire Enpath Medical Corp. for $14.38 per share in a transaction valued at $102 million, including debt.

A tender offer for the shares will begin no later than May 8, a company news release stated.

A termination fee of $3 million is included in the agreement, according to an 8-K filing with the Securities and Exchange Commission.

Greatbatch will fund the transaction, expected to close in June, with available cash. Both companies' boards of directors have unanimously approved the deal.

"Our strategies for product innovation and growth are nicely aligned and together we believe we can accelerate the delivery of new product offerings to our customers," Enpath president and chief executive officer John C. Hertig said in the release.

"Greatbatch's financial strength provides incremental funding for our product development pipeline initiatives."

Banc of America Securities LLC is acting as financial adviser to Greatbatch, and Hodgson Russ LLP is legal counsel.

Greene Holcomb & Fisher LLC is acting as financial adviser to Enpath, and Lindquist & Vennum PLLP is legal counsel to Enpath.

Enpath is a Minneapolis medical products company specializing in products for the cardiac rhythm management neuromodulation and interventional radiology markets.

Greatbatch, based in Clarence, N.Y., develops and manufactures critical components used in implantable medical devices and other applications.

Acquirer:Greatbatch Ltd.
Target:Enpath Medical Corp.
Transaction total:$102 million
Price per share:$14.38
Termination fee:$3 million
Announcement date:April 30
Expected closing:June 2007
Stock price for target:Nasdaq: NPTH; $11.13 on April 27

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.